CN114845709B - 用于治疗炎性病症的mrgprx2拮抗剂 - Google Patents
用于治疗炎性病症的mrgprx2拮抗剂 Download PDFInfo
- Publication number
- CN114845709B CN114845709B CN202080087623.0A CN202080087623A CN114845709B CN 114845709 B CN114845709 B CN 114845709B CN 202080087623 A CN202080087623 A CN 202080087623A CN 114845709 B CN114845709 B CN 114845709B
- Authority
- CN
- China
- Prior art keywords
- compound
- composition
- optionally substituted
- alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931183P | 2019-11-05 | 2019-11-05 | |
| US62/931,183 | 2019-11-05 | ||
| US201962931698P | 2019-11-06 | 2019-11-06 | |
| US62/931,698 | 2019-11-06 | ||
| US202063046461P | 2020-06-30 | 2020-06-30 | |
| US63/046,461 | 2020-06-30 | ||
| PCT/US2020/059201 WO2021092240A1 (en) | 2019-11-05 | 2020-11-05 | Mrgprx2 antagonists for the treatment of inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114845709A CN114845709A (zh) | 2022-08-02 |
| CN114845709B true CN114845709B (zh) | 2024-10-01 |
Family
ID=73646519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080087623.0A Active CN114845709B (zh) | 2019-11-05 | 2020-11-05 | 用于治疗炎性病症的mrgprx2拮抗剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20230029266A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054554A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7712922B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114845709B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020380395A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159766A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292690A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021092240A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| US20230029266A1 (en) | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ck12抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| JP7894535B2 (ja) * | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
| WO2025002360A1 (zh) * | 2023-06-30 | 2025-01-02 | 北京普祺医药科技股份有限公司 | 一种mrgprx2拮抗剂、药物组合物以及其用途 |
| US20250084063A1 (en) | 2023-08-18 | 2025-03-13 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| CN122206668A (zh) * | 2023-09-28 | 2026-06-12 | 上海翱路生物医药科技有限公司 | 化合物、组合物及其方法 |
| WO2025130765A1 (en) * | 2023-12-18 | 2025-06-26 | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | Compounds, compositions and methods thereof |
| WO2025160430A1 (en) | 2024-01-25 | 2025-07-31 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| WO2025163462A1 (ko) * | 2024-02-02 | 2025-08-07 | 삼진제약주식회사 | 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도 |
| WO2025222040A1 (en) | 2024-04-19 | 2025-10-23 | Escient Pharmaceuticals, Inc. | Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige |
| WO2026009854A1 (ja) * | 2024-07-01 | 2026-01-08 | 日本たばこ産業株式会社 | ピリダジノン化合物及びその医薬用途 |
| US12630562B2 (en) | 2024-08-07 | 2026-05-19 | Arcus Biosciences, Inc. | Piperidylurea compounds and methods of use thereof |
| WO2026112144A1 (en) * | 2024-11-20 | 2026-05-28 | Dewpoint Therapeutics, Inc. | Modulators of beta catenin and uses thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3493555A (en) | 1966-03-23 | 1970-02-03 | Nepera Chem Co Inc | 3-phenylazo-2,6-pyridyl dicyclopropane-carboxamide |
| US4152442A (en) | 1975-06-05 | 1979-05-01 | Lilly Industries Limited | Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| PH22076A (en) * | 1983-08-25 | 1988-05-20 | Daiichi Seiyaku Co | Benzocycloalkane derivative |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| JPH0717589B2 (ja) | 1990-01-22 | 1995-03-01 | ファイザー製薬株式会社 | 新規1,3―ジカルボニル化合物およびその組成物 |
| CH681383A5 (cg-RX-API-DMAC7.html) | 1990-04-11 | 1993-03-15 | Alusuisse Lonza Services Ag | |
| JPH05201981A (ja) | 1991-08-06 | 1993-08-10 | Ichikawa Gosei Kagaku Kk | 2−アミノ−3−ニトロ−5−ハロゲノピリジン類の製造方法 |
| US5290943A (en) | 1991-02-21 | 1994-03-01 | Ichikawa Gosei Chemical Co., Ltd. | Method of producing 2-acyl amino 5-halogenopyridine compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| WO2004069160A2 (en) | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
| WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| US7973169B2 (en) | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| BRPI0417687A (pt) | 2003-12-19 | 2007-04-03 | Pfizer | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade |
| BRPI0507278A (pt) * | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| CN1736989A (zh) | 2004-08-20 | 2006-02-22 | 中国科学院大连化学物理研究所 | 一种杂环菊酯类化合物及其在除草杀菌方面的应用 |
| US20060217370A1 (en) * | 2005-02-18 | 2006-09-28 | Ethan Burstein | Compounds useful for the treatment and prevention of pain and screening methods therefor |
| BRPI0619052A2 (pt) | 2005-11-28 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規FabKおよびFabI/K阻害剤 |
| AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| EP2035005A4 (en) * | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| US20080249081A1 (en) * | 2006-10-24 | 2008-10-09 | Roger Olsson | Compounds for the treatment of pain and screening methods therefor |
| WO2008050600A1 (en) * | 2006-10-25 | 2008-05-02 | Neugen Pharma Inc. | Therapeutic or preventive agent for intractable disease based on oxidative stress-mediated cell death as molecular background |
| WO2008063625A2 (en) | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| EP2125799A1 (en) * | 2007-02-28 | 2009-12-02 | Smithkline Beecham Corporation | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2725022B1 (de) | 2008-06-13 | 2017-03-29 | Bayer CropScience AG | Neue Amide als Schädlingsbekämpfungsmittel |
| WO2011074658A1 (ja) | 2009-12-18 | 2011-06-23 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| EA201201274A1 (ru) | 2010-03-10 | 2013-04-30 | Инджениум Фармасьютиклз Гмбх | Ингибиторы протеинкиназ |
| DE102010012594A1 (de) * | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| KR101688978B1 (ko) * | 2010-08-18 | 2016-12-26 | 중앙대학교 산학협력단 | 신규한 2-아미노 티아졸 유도체 및 이를 포함하는 항암용 조성물 |
| RU2601550C2 (ru) | 2010-12-09 | 2016-11-10 | Вокхардт Лимитед | Кетолидные соединения |
| DE102011083271A1 (de) * | 2011-09-23 | 2013-03-28 | Beiersdorf Ag | Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen |
| JP6130383B2 (ja) | 2011-09-30 | 2017-05-17 | エンドゥ ファーマシューティカルズ,インコーポレイティド | ピリジン誘導体 |
| FR2982261B1 (fr) | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| WO2014040243A1 (zh) * | 2012-09-12 | 2014-03-20 | 湖南有色凯铂生物药业有限公司 | N-取代苯基-n'-取代杂环脲类化合物及其作为抗癌药物的应用 |
| US9040712B2 (en) * | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| CN104955332B (zh) | 2013-01-30 | 2017-03-29 | 住友化学株式会社 | 防治节足害虫的方法 |
| WO2014125426A1 (en) | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
| WO2015089327A1 (en) | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| US9758505B2 (en) | 2014-02-12 | 2017-09-12 | Iteos Therapeutics | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
| CN104876878B (zh) * | 2014-02-27 | 2018-04-27 | 中国科学院广州生物医药与健康研究院 | 5-芳基酚-2烷基取代脲苯并咪唑类化合物及其应用 |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CN107001362A (zh) | 2014-10-06 | 2017-08-01 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| US10426815B2 (en) * | 2015-01-20 | 2019-10-01 | The General Hospital Corporation | Prevention and treatment of itch with an MRGPR antagonist |
| WO2016160938A1 (en) * | 2015-04-02 | 2016-10-06 | Abbvie Inc. | N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators |
| WO2017064068A1 (en) * | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| AR106679A1 (es) | 2015-11-13 | 2018-02-07 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatógenos |
| CN105924387A (zh) | 2016-04-28 | 2016-09-07 | 西安交通大学 | 一种具有抗肿瘤活性的双芳基脲化合物及其制备方法和应用 |
| PT3534899T (pt) * | 2016-11-03 | 2022-07-07 | Corvus Pharmaceuticals Inc | Compostos e métodos de modulação da cinase de células t induzível por interleucina-2 |
| WO2018114783A1 (en) | 2016-12-23 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Tetrazole containing compounds |
| BR112019018230A2 (pt) | 2017-03-02 | 2020-07-21 | Assembly Biosciences, Inc. | compostos de sulfamida cíclica e métodos de sua utilização |
| UY37957A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| CN107661328B (zh) * | 2017-11-15 | 2019-08-23 | 西安交通大学 | 呋喃香豆素类化合物在制备抗过敏药物中的应用 |
| EP3498694A1 (en) | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
| ES3043183T3 (en) * | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN108619183A (zh) * | 2018-06-04 | 2018-10-09 | 西安交通大学 | 一种白芷中香豆素类化合物的简单提取方法及其应用 |
| CN108451967B (zh) * | 2018-06-04 | 2020-06-19 | 西安交通大学 | 克拉霉素在制备抗类过敏反应药物中的应用 |
| EP4054570A1 (en) | 2019-11-05 | 2022-09-14 | Dermira, Inc | Mrgprx2 antagonists and uses thereof |
| US20230029266A1 (en) | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
-
2020
- 2020-11-05 US US17/772,467 patent/US20230029266A1/en active Pending
- 2020-11-05 EP EP20816766.8A patent/EP4054554A1/en active Pending
- 2020-11-05 CN CN202080087623.0A patent/CN114845709B/zh active Active
- 2020-11-05 CA CA3159766A patent/CA3159766A1/en active Pending
- 2020-11-05 JP JP2022526326A patent/JP7712922B2/ja active Active
- 2020-11-05 WO PCT/US2020/059201 patent/WO2021092240A1/en not_active Ceased
- 2020-11-05 AU AU2020380395A patent/AU2020380395A1/en active Pending
-
2022
- 2022-05-02 IL IL292690A patent/IL292690A/en unknown
-
2024
- 2024-10-22 US US18/923,566 patent/US12502380B2/en active Active
-
2025
- 2025-07-11 JP JP2025117223A patent/JP2025148482A/ja active Pending
- 2025-10-03 US US19/349,768 patent/US20260027089A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4054554A1 (en) | 2022-09-14 |
| US12502380B2 (en) | 2025-12-23 |
| JP2025148482A (ja) | 2025-10-07 |
| JP7712922B2 (ja) | 2025-07-24 |
| US20250057816A1 (en) | 2025-02-20 |
| US20230029266A1 (en) | 2023-01-26 |
| CA3159766A1 (en) | 2021-05-14 |
| AU2020380395A1 (en) | 2022-05-26 |
| US20260027089A1 (en) | 2026-01-29 |
| JP2022554389A (ja) | 2022-12-28 |
| CN114845709A (zh) | 2022-08-02 |
| IL292690A (en) | 2022-07-01 |
| WO2021092240A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7712922B2 (ja) | 炎症性障害を治療するためのMrgprX2アンタゴニスト | |
| CN114901280B (zh) | MrgprX2拮抗剂及其用途 | |
| CN114728919B (zh) | MrgprX2拮抗剂及其用途 | |
| IL296355A (en) | Oral hsp90 inhibitor formulations and related methods | |
| CA2838741A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| AU2007218596A1 (en) | Stabilized pharmaceutical composition | |
| JP2019521170A (ja) | 置換ジアザヘテロ−二環式化合物およびそれらの使用 | |
| JP2017528494A (ja) | sGC刺激剤 | |
| JP7636742B2 (ja) | 制御送達性クロマカリムプロドラッグ | |
| EP2008658A1 (en) | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | |
| KR20170141774A (ko) | 항바이러스 및 항염증 치료제의 치료 조합물 | |
| CN113365617B (zh) | 用于医学疾病治疗的一氧化碳前药 | |
| CN117545479A (zh) | Pi3k抑制剂、纳米制剂及其用途 | |
| WO2021218992A1 (zh) | 取代的吡咯烷类化合物及其在药物中的应用 | |
| CN116134038A (zh) | Irak4抑制剂及其局部用途 | |
| KR100388605B1 (ko) | 용해도 및 용해속도가 향상된 이트라코나졸의 액상 조성물 및 이를 이용한 이트라코나졸 제제와 그 제조방법 | |
| KR20240019340A (ko) | 헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물 | |
| ES2348640T3 (es) | Dispersiones solidas comprendiendo tacrolimus. | |
| IL267218B2 (en) | A new multi-purpose drug for the treatment of diseases in mammals | |
| AU2012271746A1 (en) | Modified release of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl) benzamide solubilized using organic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |